课题基金 / 基金详情

Pathogenesis of thrombotic microangiopathies

Pathogenesis of thrombotic microangiopathies
血栓性微血管病的发病机制
批准号:
10608740
负责人:
X. Long Zheng
金额:
$51.91万
依托单位国家:
美国
项目类别:
财政年份:
2023
资助国家:
美国
项目状态:
未结题
起止时间:
2023-08-15 至 2027-07-31

项目摘要

项目成果

X. Long Zheng的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY Immune thrombotic thrombocytopenic purpura (iTTP) is a rare but potentially fatal blood disorder, resulting from autoantibodies against ADAMTS13, a plasma metalloprotease that cleaves endothelial von Willebrand factor. Despite progresses being made in past decades, major gap remains in our understanding the pathogenesis of iTTP. The proposed study will test the hypotheses that: 1) distinct molecular signatures in the complementarity determining region (CDR)-3 and the VDJ rearrangements in the variable regions of immunoglobulins (Ig) against ADAMTS13 determine their functionalities (e.g., the inhibitory vs. activating) in patients with iTTP; 2) the abnormalities in ANKRD26 and 36 gene family, initially identified to associate with hereditary thrombocytopenia, may also play a role in pathogenesis of iTTP, likely through disruption of megakaryocytopoiesis and enhanced immune inflammatory responses. The proposed study will use various cutting-edge tools and animal models to test these hypotheses. The results of the proposed study will shed new light on pathogenesis of iTTP and other immune thrombotic disorders. The findings may help develop novel strategies for therapeutic interventions for such disorders.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Novel Therapeutics for Acquired Thrombotic Thrombocytopenic Purpura
Novel Therapeutics for Acquired Thrombotic Thrombocytopenic Purpura
Novel Therapeutics for Acquired Thrombotic Thrombocytopenic Purpura
Novel Therapeutics for Acquired Thrombotic Thrombocytopenic Purpura
海外基金